JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Boston Scientific Corp.

Chiusa

SettoreSettore sanitario

102.73 -0.47

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

102.52

Massimo

103.81

Metriche Chiave

By Trading Economics

Entrata

125M

797M

Vendite

398M

5.1B

P/E

Media del settore

62.818

34.393

EPS

0.75

Margine di Profitto

15.748

Dipendenti

53,000

EBITDA

-848M

364M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+21.16% upside

Dividendi

By Dow Jones

Utili prossimi

22 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

4.7B

158B

Apertura precedente

103.2

Chiusura precedente

102.73

Notizie sul Sentiment di mercato

By Acuity

41%

59%

136 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Boston Scientific Corp. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 lug 2025, 11:16 UTC

Utili

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

23 apr 2025, 12:16 UTC

Utili
I principali Market Mover

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3 mar 2025, 12:35 UTC

Acquisizioni, Fusioni, Takeovers

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5 feb 2025, 12:23 UTC

Utili

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23 lug 2025, 10:32 UTC

Utili

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23 lug 2025, 10:31 UTC

Utili

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23 lug 2025, 10:30 UTC

Utili

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23 lug 2025, 10:30 UTC

Utili

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23 lug 2025, 10:30 UTC

Utili

Boston Scientific 2Q EPS 53c >BSX

23 lug 2025, 10:30 UTC

Utili

Boston Scientific 2Q Sales $5.06B >BSX

23 lug 2025, 10:30 UTC

Utili

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23 lug 2025, 10:30 UTC

Utili

Boston Scientific 2Q Adj EPS 75c >BSX

23 lug 2025, 10:30 UTC

Utili

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

23 lug 2025, 10:30 UTC

Utili

Boston Scientific Sees 3Q EPS 44c-EPS 46c >BSX

23 apr 2025, 10:32 UTC

Utili

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23 apr 2025, 10:31 UTC

Utili

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23 apr 2025, 10:30 UTC

Utili

Boston Scientific 1Q EPS 45c >BSX

23 apr 2025, 10:30 UTC

Utili

Boston Scientific 1Q Adj EPS 75c >BSX

23 apr 2025, 10:30 UTC

Utili

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23 apr 2025, 10:30 UTC

Utili

Boston Scientific 1Q Sales $4.66B >BSX

23 apr 2025, 10:30 UTC

Utili

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23 apr 2025, 10:30 UTC

Utili

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23 apr 2025, 10:30 UTC

Utili

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23 apr 2025, 10:30 UTC

Utili

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3 mar 2025, 11:59 UTC

Acquisizioni, Fusioni, Takeovers

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 mar 2025, 11:58 UTC

Acquisizioni, Fusioni, Takeovers

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 mar 2025, 11:58 UTC

Acquisizioni, Fusioni, Takeovers

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 feb 2025, 21:33 UTC

Utili

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 15:20 UTC

Utili

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 11:39 UTC

Utili

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

Confronto tra pari

Modifica del prezzo

Boston Scientific Corp. Previsione

Obiettivo di Prezzo

By TipRanks

21.16% in crescita

Previsioni per 12 mesi

Media 124.96 USD  21.16%

Alto 140 USD

Basso 112 USD

Basato su 24 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Boston Scientific Corp. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

24 ratings

23

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

102.95 / 104.93Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

136 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.